Abstract Types

CRA
Clinical Review Abstract

LBA
Late-Breaking Abstract

TPS
Trials in Progress Abstract

e
Abstracts selected for publication but not presentation at the Annual Meeting

^
Abstracts granted an exception in accordance with ASCO's Conflict of Interest Policy



Levels of circulating natural killer T and natural killer cells in breast cancer patients.

Sub-category:
Immunobiology

Category:
Tumor Biology

Meeting:
2013 ASCO Annual Meeting

Abstract No:
e22034

Citation:
J Clin Oncol 31, 2013 (suppl; abstr e22034)

Publication-only abstracts (abstract number preceded by an "e"), published in conjunction with the 2013 Annual Meeting but not presented at the Meeting, can be found online only.

Author(s): Mya Sanda Thein, Saranya Chumsri, James Eeast, Junxin Li, Susan Kesmodel, Ting Bao, Steven J. Feigenberg, Katherine Hanna Tkaczuk, Tonya Webb; Johns Hopkins University School of Medicine, Baltimore, MD; University of Maryland, Marlene and Stewart Greenebaum Cancer Center, Baltimore, MD; University of Maryland, School of Medicine, Baltimore, MD

Abstract Disclosures


Abstract:

Background: Invariant natural killer T (iNKT) cells are a unique subset of T lymphocytes that express markers characteristic of both T cells and natural killer (NK) cells. Following activation, iNKT cells rapidly produce a variety of cytokines and activate many other immune cells, thus iNKT cells are key mediators of innate immune responses (IIR) against tumors. The aim of this study was to assess the percentage (%) of iNKT, NKT-like, and NK cells in the peripheral blood of healthy volunteers (HV) and breast cancer (BC) patients. Methods: The % of circulating iNKT (Va24Ja18+CD3+), NKT-like (CD3+CD16CD56+), and NK (CD3-CD16CD56+) cells was analyzed by standardized flow cytometry in 22 newly diagnosed stage 0-3 BC patients and 27 HV. Luminal A BC was defined as ER/PR+≥1%, HER2- Ki67<20%. Differences between groups were assessed using the Mann-Whitney U test for nonparametric data and ANOVA for ≥ 3 groups. Results: iNKT cells % in BC patients (ages: 37-75) was significantly lower compared to HV (ages: 21-64) (Mean: 0.32 vs 0.12, p=0.0036). Among BC patients, NK cells were lower in patients aged ≥50 yrs (p=0.003) and with BMI ≥ 30 (p=0.0036). NK cell % was higher in Asians compared to other races. Patients with luminal A BC, which generally have the best prognosis, have a significantly higher % of NKT-like cells. Conclusions: Interestingly our data shows that older and obese BC patients have lower % of circulating NK cells, while patients with luminal A tumors have a higher % of NKT-like and a lower % of iNKT cells. Further studies on the effects of BMI and aging on IIR as well as functional studies are needed to better understand immunosenescence-related increasing incidence of cancers and IIR-mediated anti-tumor activity in BC patients. [caption]iNKT, NKT-like, and NK cells (% lymphocytes) by age, BMI, race, and pathology in BC patients.[/captions]

n iNKT NKT-like NK
Age <50 yr 11 0.15±0.18 10.91±8.7 19.8±7.5*
≥50 yr 11 0.11±0.13 7.45±6.4 10.4±4.7
BMI <30 15 0.15±0.18 10.96±8.35 17.71±7.9*
≥30 7 0.09±0.08 5.37±4.33 9.73±3.39
Race Asian 3 0.13±0.11 18.72±9.23 26.51±10.06*
Caucasian 9 0.15±0.14 7.66±6.94 14.27±5.7
African-American 10 0.11±0.18 7.68±6.38 12.58±6.1
Pathology Luminal A 7 0.05±0.08* 10.89±8.01* 13.24±5.2
Non-Luminal A 15 0.16±0.17 8.38±7.67 16.07±8.6

*p value <0.05.

 

  Other Abstracts in this Sub-Category:

 

1. Inflammatory phenotype of classical (CD14++CD16-) monocytes in patients with advanced non-small cell lung cancer.

Meeting: 2013 ASCO Annual Meeting Abstract No: 11071 First Author: F. M. McCarthy
Category: Tumor Biology - Immunobiology

 

2. Cancer-testis antigens in triple-negative and locally advanced breast cancer.

Meeting: 2013 ASCO Annual Meeting Abstract No: 11072 First Author: S. J. Harris
Category: Tumor Biology - Immunobiology

 

3. Analysis of the prognostic impact of Treg-related genes in tumor and stroma in resectable NSCLC.

Meeting: 2013 ASCO Annual Meeting Abstract No: 11073 First Author: M. Usó
Category: Tumor Biology - Immunobiology

 

More...